Weekly Biotech Recap: ScinoPharm's FDA Approval, Genelux's Olvi-Vec Success, GLUE's MRT-8102 Advancements, and More

ScinoPharm receives FDA approval for Glatiramer Acetate Injection for multiple sclerosis treatment. Genelux reports durable responses in systemic Olvi-Vec lung cancer trials, while Neumora demonstrates positive data for NMRA-511 in Phase 1 Alzheimer's disease agitation study. GSK unveils encouraging results in chronic Hepatitis B trial of Bepirovirsen, and HUTCHMED's Sovleplenib meets primary endpoint in Warm Autoimmune Hemolytic Anaemia. GLUE unveils promising Phase 1 data for MRT-8102 in cardiovascular risk participants.